Cover Picture: The ageing society today is confronted with an epidemic of chronic diseases, among which neurodegenerative diseases present an ever-growing medical and social burden. Ageing is a major risk factor for neurodegeneration, and that the prevalence of age-related neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, etc. has dramatically increased in recent decades. Unfortunately, no treatments have been shown to slow the neurodegeneration in patients with these diseases. Thus, to develop successful interventions, it is extremely important to investigate the basic mechanisms of ageing and their role in the onset and progression of neurodegenerative diseases, the results of which will facilitate the discovery of potential targets for novel therapies for neurodegenerative diseases. In addition, early clinical intervention is crucial for the management of patients with neurodegenerative diseases. However, the lack of specific biomarkers for their accurate diagnosis hinders early clinical diagnosis and intervention of these devastating diseases. Furthermore, the discovery and development of novel effective therapies for neurodegenerative diseases largely depends on reliable biomarkers of mechanism and target engagement to accelerate therapeutic development.
view this paper